March 17th - Jiuzhou PharmaceuticalThe company issued an announcement stating that its wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd. (formerly Zhejiang Siwei Pharmaceutical Technology Co., Ltd.), received the Drug Registration Certificate for Vortioxetine Hydrobromide Tablets issued by the National Medical Products Administration.
The approved drug is vortioxetine hydrobromide tablets, available in tablet form (5mg and 10mg) and classified as a Class 4 chemical drug. This drug is primarily used for the treatment of major depressive disorder (MDD) in adults. Vortioxetine hydrobromide tablets are manufactured by Lundbeck (Denmark) and Takeda (Japan).The product was jointly developed and approved for market launch in the United States in September 2013, and in China in November 2017.

According to the announcement, the total sales (terminal price) of vortioxetine hydrobromide tablets in the domestic medical and retail markets in 2024 were approximately RMB 214 million. As of the date of the announcement, Jiuzhou Pharmaceutical 's cumulative R&D investment in this project was approximately RMB 12.62 million.

Jiuzhou Pharmaceutical stated that this approval further enriches the company's product pipeline and will help enhance the market competitiveness of its products.

https://finance.eastmoney.com/a/202603173674947324.html